“Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 4, July 2023, p. s226, https://doi.org/10.25251/skin.7.supp.226.